TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3310843
Drug: Boiled rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled rice (90 g, raw, boiled in salted water)
Study: 28428736
Drug: Fructose supplementation
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose supplementation (4 g/kg BM)
Study: 28428736
Drug: Glucose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose supplementation (4 g/kg BM)
Study: 25913040
Drug: MMF +
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF + Pantoprazole (PAN) 40 mg
Study: 25913040
Drug: EC-MPS +
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EC-MPS + Pantoprazole (PAN) 40 mg
Study: 19492646
Drug: platform-enlarged implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: platform-enlarged implants
Study: 19492646
Drug: control implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: control implants with an abutment as large as the implant platform
Study: 19492646
Drug: control implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: control implants with a reduced abutment
Study: 19492646
Drug: submerged implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: submerged implants with an enlarged platform
Study: 17108797
Drug: Therapeutic taping
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic taping + physical therapy
Study: 15346082
Drug: Both implants
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implants (LISS and distal femoral nail)
Study: 3902379
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg bezafibrate per day
Study: 3902379
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg fenofibrate per day
Study: 22242678
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg daily for 6 weeks (Control)
Study: 22242678
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of desloratadine: 5 mg daily for the first 2 weeks, 10 mg daily for the second 2 weeks, and 20 mg daily for the final 2 weeks (Intervention)
Study: 18408525
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75 mg/day (up to 300 mg/day)
Study: 18408525
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg/day (up to 60 mg/day)
Study: 15741037
Drug: No cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cold therapy (control)
Study: 10420136
Drug: 0.16% RBG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.16% RBG cream
Study: 2147235
Drug: Imipramine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (dose adjusted to optimal plasma levels of 400-600 nM)
Study: 6988039
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms inhaled salbutamol powder
Study: 6988039
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms inhaled salbutamol powder
Study: 6988039
Drug: 800 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micrograms inhaled salbutamol powder
Study: 30334096
Drug: GLE/PIB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLE/PIB treatment for 12 weeks
Study: 28350758
Drug: Vaginal gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel containing 50μg estriol for 12 weeks (group A)
Study: 28350758
Drug: Estriol vaginal
Normalized name: estriol Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol vaginal gel after surgery (group A1)
Study: 28350758
Drug: No estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: No estrogen treatment (group B)
Study: 28350758
Drug: Estriol treatment
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol treatment after surgery (group A1)
Study: 28350758
Drug: No estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No estriol treatment after surgery (group A2)
Study: 25293727
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with external beam radiotherapy (EBRT) (45-50.4 Gy)
Study: 25293727
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without external beam radiotherapy (EBRT)
Study: 25293727
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with pre-anastomosis intraoperative electron radiation therapy (IOERT) boost (10-15 Gy)
Study: 25293727
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with external beam radiotherapy (EBRT)
Study: 23803042
Drug: Ginger supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger supplement (750 mg per capsule, 4 capsules daily for 6 weeks)
Study: 23803042
Drug: Water-based exercise
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based exercise + Ginger supplement
Study: 22292254
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2), initiated within 1-3 days post-surgery, for at least 20 sessions (one session per day)
Study: 16725234
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A/B vaccine Twinrix (GSK)
Study: 16725234
Drug: Co-administered hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered hepatitis A vaccine, Havrix (GSK) + hepatitis B vaccine Engerix-B (GSK)
Study: 16725234
Drug: Co-administered hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered hepatitis A vaccine, Vaqta (Sanofi-Pasteur MSD) + hepatitis B vaccine HB VAX PRO (Sanofi-Pasteur MSD)
Study: 11479155
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with serum creatinine > 6 mg/dL (12 patients)
Study: 11479155
Drug: MHD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHD patients with therapy longer than 10 years (8 patients)
Study: 10096818
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Gortex bags, high-powered vacuum cleaner, benzyl alcohol and tannic acid spray)
Study: 10096818
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (light cotton bags, cheap vacuum cleaner, water spray)
Study: 7995325
Drug: 17 beta-oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-oestradiol (9 mg)
Study: 30712745
Drug: 2% lavender
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lavender essential oil inhalation for 20 minutes every night for one month
Study: 30712745
Drug: Placebo (distilled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (distilled water) inhalation for 20 minutes every night for one month
Study: 28584187
Drug: adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab (40 mg every 2 weeks)
Study: 24934402
Drug: MAT-Fel d
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAT-Fel d 1 vaccine
Study: 17868757
Drug: Measurement-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement-based treatment protocols
Study: 31480601
Drug: Pregabalin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (oral solution of pregabalin 150 mg twice daily for 14 days)
Study: 27876198
Drug: Monovalent rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent rotavirus vaccine (RV1)
Study: 20152998
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + GLP-1
Study: 9244203
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg/d for 3 days or 500 mg/d for 6 days)
Study: 8310466
Drug: Long-term outpatient
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term outpatient treatment in alcoholics with previous suicidal behavior
Study: 2939574
Drug: Alcuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.25 mg/kg
Study: 30202946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omega-3 and losartan
Study: 25735918
Drug: Bemfola (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemfola (150 IU daily)
Study: 25735918
Drug: Gonal-f (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonal-f (150 IU daily)
Study: 23967725
Drug: Capecitabine conjugated
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine conjugated with a new biological agent
Study: 3068160
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg) + Rosaprostol (2 g) daily
Study: 3068160
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg) + Placebo
Study: 3068160
Drug: NSAIDs (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (diclofenac sodium 50 mg, piroxicam 20 mg, acetylsalicylic acid 500 mg)
Study: 3068160
Drug: Rosaprostol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosaprostol (2 g)
Study: 28937272
Drug: Movement music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement music therapy (MMT) group, 35 participants
Study: 27627596
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hygiene education only)
Study: 21599573
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of red wine/day for women (16 g ethanol/day) or 300 ml of red wine/day for men (33 g ethanol/day)
Study: 16766434
Drug: Conjugated estrogens/medroxyprogesterone
Normalized name: Conjugated Estrogens/Medroxyprogesterone Acetate 0.625 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) doses: 0.625/2.5, 0.45/1.5, or 0.3/1.5 mg daily for 24 weeks
Study: 8904521
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) 300 U kg‐1, i.v. or s.c., once, combined with parenteral and oral iron
Study: 8904521
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy only
Study: 2125737
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (mean daily dose of 587 +/- 49 mg)
Study: 6998597
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg of methylprednisolone sodium succinate (MPN)
Study: 6998597
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg of mannitol placebo (PL)
Study: 31056884
Drug: Oral Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Alprazolam tablets once a day
Study: 28356271
Drug: Cashew diet
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cashew diet (28-64 g/d)
Study: 21736808
Drug: Dried plum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried plum (100 g/d)
Study: 7956622
Drug: Daytime insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daytime insulin infusion (mean 1.5 +/- 0.1 IU/h)
Study: 7956622
Drug: Nocturnal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nocturnal insulin infusion (mean 1.5 +/- 0.1 IU/h)
Study: 7956622
Drug: Nocturnal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nocturnal insulin infusion
Study: 7956622
Drug: Daytime insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daytime insulin infusion
Study: 3597264
Drug: Inspiratory resistive
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory resistive loads (8.9‐35.7 cmH2O X l‐1 X s)
Study: 27759857
Drug: Topical squalamine
Normalized name: Squalane
DrugBank: Squalane (DB11420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical squalamine and intravitreal ranibizumab 0.5 mg
Study: 27759857
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (control)
Study: 25045235
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine infusion during general anesthesia
Study: 25045235
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline equivalent to ketamine infusions
Study: 15259481
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 10 mg/kg triclabendazole
Study: 15259481
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 10 mg/kg triclabendazole
Study: 10223765
Drug: Combined adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined adjuvant chemotherapy and radiotherapy
Study: 1403921
Drug: 3 mm
Normalized name: Adapta-Cap G, 33 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mm access preparations wetted with mercury-rich amalgam before restoration
Study: 1403921
Drug: 3 mm
Normalized name: Adapta-Cap G, 33 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mm access preparations restored unwetted
Study: 3886191
Drug: Amrinone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (1.5 mg/kg tid increasing to a maximum dosage of 200 mg tid)
Study: 26911981
Drug: Lidocaine Injections
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine Injections (LI)
Study: 26911981
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Physical Therapy and Lidocaine Injections (PT + LI)
Study: 20173440
Drug: Acupuncture needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture needling treatment and self neck-stretching exercises
Study: 18243639
Drug: Subcutaneous tetrodotoxin
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tetrodotoxin administered over Days 1-4
Study: 18243639
Drug: Subcutaneous tetrodotoxin
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tetrodotoxin
Study: 10397520
Drug: One stage
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One stage full-mouth disinfection treatment
Study: 10397520
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (scaling and root planing per quadrant at 2-week intervals)
Study: 8655981
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide (NO) treatment
Study: 1515957
Drug: Nicardipine (NICAR)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NICAR) 10 micrograms.kg‐1.min‐1 over 10 minutes followed by an infusion at 4 mg.kg‐1.min‐1
Study: 7124431
Drug: Motipress (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motipress (combined anxiolytic/antidepressant)
Study: 27476789
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once per day (or 30 mg once per day for specific patients)
Study: 27476789
Drug: Warfarin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose adjusted to maintain INR between 2.0 and 3.0)
Study: 25181622
Drug: Rectally administrated
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectally administrated 800 mg misoprostol
Study: 22248028
Drug: β‐elemene at
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐elemene at 45 mg/kg
Study: 19693500
Drug: Dose-dense therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense therapy (CEOP/IMVP-Dexa)
Study: 19693500
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (CHOP)
Study: 18584415
Drug: E(2) 2
Normalized name: (E)-2-butenedioic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 2 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day
Study: 18584415
Drug: E(2) 2
Normalized name: (E)-2-butenedioic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 2 mg/day
Study: 18584415
Drug: E(2) 2
Normalized name: (E)-2-butenedioic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 2 mg/day plus dienogest 2 mg/day
Study: 18584415
Drug: E(2) 2
Normalized name: (E)-2-butenedioic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 2 mg/day plus norethisterone acetate (NETA) 1 mg/day
Study: 10206086
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg alone
Study: 10206086
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg with ketoconazole 200 mg (4 days pretreatment and concomitant administration)
Study: 31955164
Drug: 25-gauge illumination-aided
Normalized name: GINGI-AID 25 % Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-gauge illumination-aided scleral buckling (SB) combined with hyaluronate injection after subretinal fluid drainage.
Study: 31955164
Drug: Conventional SB
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional SB with binocular indirect ophthalmoscope combined with air injection.
Study: 30865795
Drug: Antibiotics (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (400 mg oral doxycycline and 400 mg oral metronidazole)
Study: 28338503
Drug: Crystalline valsartan/sacubitril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline valsartan/sacubitril (LCZ696) 400 mg daily
Study: 28338503
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg daily
Study: 28338503
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of free valsartan 320 mg and sacubitril 200 mg
Study: 23871265
Drug: Ketoprofen (3mg/kg)
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen (3mg/kg) administered intramuscularly for 3 days p.p.
Study: 21282280
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch (9.5 mg/24 hours)
Study: 21282280
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (6 mg twice daily)
Study: 18463427
Drug: Garlic (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (0.1 g/kg b.w. daily for 1 month)
Study: 16415635
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive therapy using fixed-dose combinations of two antihypertensive agents.
Study: 16415635
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive therapy (implied control group).
Study: 8904627
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg butorphanol nasal spray every 6 h
Study: 8904627
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg cimetidine tablet every 6 h
Study: 8904627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of butorphanol nasal spray and cimetidine every 6 h
Study: 1414906
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg SR verapamil with a standardized meal
Study: 1414906
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg SR verapamil on an empty stomach
Study: 1414906
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous verapamil
Study: 25271117
Drug: Insulin initiation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin initiation and titration
Study: 22541308
Drug: Intense rehabilitation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense rehabilitation therapies with acupuncture (5 times per week for 12 weeks)
Study: 22541308
Drug: Intense rehabilitation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense rehabilitation therapies without acupuncture (5 times per week for 12 weeks)
Study: 22541308
Drug: Acupuncture added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture added to rehabilitation therapies (weeks 16-28)
Study: 22541308
Drug: Combined groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined groups after intense therapies
Study: 15632815
Drug: Flexible diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible diuretic titration (DT)
Study: 11854636
Drug: Normal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oral glucose tolerance test results
Study: 10188899
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (mitomycin-C 8 mg m(‐2), vinblastine 6 mg m(‐2), cisplatin 50 mg m(‐2) - MVP) followed by surgery
Study: 7564895
Drug: Hexyl nicotinate
Normalized name: Hexyl nicotinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexyl nicotinate (HN) 0.5% ethanol solution